|1.||Ribas, Antoni: 19 articles (11/2015 - 12/2005)|
|2.||Gomez-Navarro, Jesus: 15 articles (02/2013 - 12/2005)|
|3.||Glaspy, John A: 8 articles (11/2015 - 12/2005)|
|4.||Kirkwood, John M: 7 articles (02/2013 - 10/2007)|
|5.||Jalil, Jason: 7 articles (01/2013 - 01/2008)|
|6.||Chmielowski, Bartosz: 6 articles (11/2015 - 10/2009)|
|7.||Tarhini, Ahmad A: 6 articles (03/2013 - 10/2007)|
|8.||Comin-Anduix, Begoña: 6 articles (01/2013 - 12/2005)|
|9.||Camacho, Luis H: 5 articles (11/2015 - 12/2005)|
|10.||Maio, Michele: 5 articles (04/2015 - 10/2010)|
|1.||Melanoma (Melanoma, Malignant)
06/01/2007 - "A subset of patients receiving CP-675,206 demonstrated antitumor efficacy with partial response or complete response of metastatic melanoma. "
08/01/2013 - "Is tremelimumab beneficial in advanced melanoma?"
08/15/2008 - "We monitored the immune responses of 10 melanoma patients included in a phase II clinical trial, which evaluated the efficacy of a second line of therapy of tremelimumab anti-CTLA-4 mAb in patients with metastatic melanoma. "
11/01/2015 - "We reviewed the outcomes of patients with advanced melanoma enrolled in four phase 1 and 2 tremelimumab trials at two sites to determine response rates and long-term survival. "
06/15/2014 - "This signature was validated in an independent population of 260 treatment-naïve patients with melanoma enrolled in a multicenter phase III study of tremelimumab. "
01/01/2016 - "This delayed, yet dramatic antitumor response suggests that tremelimumab may hold promise in the treatment of solid tumors. "
01/01/2009 - "In this study, biopsies of selected accessible tumor lesions from patients treated with tremelimumab were examined to further elucidate the mechanism of its antitumor activity. "
01/01/2016 - "Tremelimumab-associated tumor regression following after initial progression: two case reports."
08/01/2015 - "We hypothesized that these cancers could respond to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibition with tremelimumab by potentiating T-cell activation. "
07/01/2013 - "Tremelimumab at a dose of 15 mg/kg IV every 90 days was administered until tumor progression or severe toxicity. "
|3.||Colorectal Neoplasms (Colorectal Cancer)
10/01/2007 - "Phase III clinical trials to confirm the role of tremelimumab in the treatment of metastatic melanoma are ongoing, as are phase II trials in patients with NSCLC and colorectal cancer."
07/20/2010 - "Safety and efficacy of tremelimumab (CP-675,206), a fully human anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) monoclonal antibody, were assessed in patients with treatment-refractory colorectal cancer. "
07/20/2010 - "Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer."
01/01/2013 - "Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells."
|4.||Neoplasm Metastasis (Metastasis)
10/01/2013 - "Although the effect size was small in our phase 2 trial, tremelimumab seemed to have encouraging clinical activity and an acceptable safety and tolerability profile in previously treated patients with advanced malignant mesothelioma. "
12/01/2015 - "Tremelimumab demonstrated therapeutic activity in different malignancies, including malignant pleural mesothelioma (MPM); however, continued research could improve the therapeutic index of this agent. "
12/01/2015 - "Tremelimumab for the treatment of malignant mesothelioma."
04/01/2015 - "Our results suggest that the intensified schedule of tremelimumab investigated seems to have clinical and immunological activity in patients with advanced malignant mesothelioma, and a good safety profile. "
04/01/2015 - "We therefore investigated the efficacy and safety of an intensified schedule of tremelimumab in patients with advanced malignant mesothelioma. "
|2.||cytotoxic T-lymphocyte antigen 4
|6.||Biological Markers (Surrogate Marker)
|7.||Interferon Alfa-2b (Interferon Alfa 2b)
|1.||Drug Therapy (Chemotherapy)